<DOC>
	<DOCNO>NCT00047801</DOCNO>
	<brief_summary>The purpose study determine effectiveness safety TLK286 give intravenously every three week combination docetaxel ( Taxotere ) treatment patient non-small cell lung cancer resistant platinum-based chemotherapy .</brief_summary>
	<brief_title>Phase 1-2a Dose-Ranging Study TLK286 Combination With Docetaxel Platinum-Resistant Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Inclusion criterion include : Histologically confirm nonsmall cell bronchogenic carcinoma , include squamous cell carcinoma , undifferentiated carcinoma , adenocarcinoma , mixed ( adenocarcinoma squamous cell carcinoma ) , bronchoalveolar carcinoma , large cell carcinoma Stage IV Stage IIIB Progressed firstline therapy platinumcontaining regimen advance metastatic treatment regimen At least 18 year age Good performance status ( ECOG 0 1 ) Adequate liver , renal , bone marrow function Exclusion criterion include : Pregnant lactate woman Treatment one cytotoxic therapy Prior radiation whole pelvis Unstable medical condition uncontrolled cardiac arrhythmia Patients know history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>